



ASX: EIQ RELEASE

13 September 2024

**ECHO IQ WEBINAR 12 SEPTEMBER 2024  
RECORDING AVAILABLE**

**Sydney:** Artificial Intelligence and Medical Technology company Echo IQ (“the Company”) (ASX: EIQ) held an Investor Webinar on 12 September 2024.

Mr Deon Strydom, Echo IQ Chief Commercial Officer, and Professor Geoff Strange, Chief Research and Strategy Officer, provided an update on the Company following the release of the clinical study results announced on 3 September 2024.

A recording of the session can be found here: [Echo IQ Webinar 12 September 2024](#)

-ENDS-

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Media Enquiries:**

Philip Woolff, Chief Operating Officer  
[philip.woolff@echoiq.ai](mailto:philip.woolff@echoiq.ai) / [marketing@echoiq.ai](mailto:marketing@echoiq.ai) / +61 (0)490 030 620

**Investor Enquiries:**

Andrew Grover, Executive Chair  
[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / [investors@echoiq.ai](mailto:investors@echoiq.ai)

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.